Clinical Trial Update: Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study of eltanexor with venetoclax for relapsed or refractory myelodysplastic syndromes and acute myeloid leukemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Eltanexor (eltanexor)
• Venetoclax (venetoclax)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Relapsed Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome | Phase 1 | Status: RECRUITING